论文部分内容阅读
目的探讨放射性核素131I标记抗CD80单克隆抗体及标记物在荷淋巴瘤裸鼠体内的放射免疫显像。方法采用Iodogen法进行抗CD80单克隆抗体4E5的131I标记,并对标记抗体的免疫活性及稳定性进行分析。经荷淋巴瘤裸鼠模型尾静脉注入剂量为7.4 MBq/0.2 ml的131I-4E5抗体,分别于注药后24 h、48 h和72 h进行SPECT平面显像,采用感兴趣区(ROI)技术进行半定量分析,计算肿瘤与非瘤组织的放射性计数比值(T/NT)。显像结束后处死荷瘤裸鼠,分别取肿瘤、血等14种脏器或组织称重并测量其放射性计数,计算各脏器或组织的每克组织百分注射剂量率(%ID/g)。结果131I标记单克隆抗体4E5的标记率为(78.3±2.4)%,放射化学纯度为(95.7±1.8)%;131I-4E5抗体与Raji细胞的最大结合率为(36.1±2.6)%,131I-4E5抗体加入到血清中放置3天后放化纯度仍>90%;荷瘤裸鼠注入131I-4E5抗体后,随时间的延长,肿瘤部位放射性浓聚逐渐增加,在72 h时肿瘤显影最为清晰,T/NT值此时最大达到3.2。结论131I-4E5抗体在荷淋巴瘤裸鼠体内具有靶向定位能力,可获得良好的放射免疫显像图像,为进一步利用131I-4E5进行淋巴瘤CD80为靶点的放射免疫治疗奠定了基础。
Objective To investigate the radioimmunoimaging of 131I-labeled anti-CD80 monoclonal antibody and its marker in nude mice bearing lymphoma. Methods Iodogen method was used to detect the 131I of anti-CD80 monoclonal antibody 4E5, and the immunological activity and stability of the labeled antibody were analyzed. The 131I-4E5 antibody was injected into the caudal vein of nude mice bearing nude mice model at a dose of 7.4 MBq / 0.2 ml. The SPECT images were taken at 24 h, 48 h and 72 h after injection. The ROI technique Semi-quantitative analysis was performed to calculate the radioactive count ratio (T / NT) between tumor and non-tumor tissues. The tumor-bearing nude mice were sacrificed after the imaging, and 14 kinds of organs or tissues such as tumor and blood were weighed and their radioactivity counts were measured to calculate the per unit dose rate (% ID / g) of each organ or tissue ). RESULTS: The labeling rate of 131I-labeled monoclonal antibody 4E5 was (78.3 ± 2.4)% and the radiochemical purity was (95.7 ± 1.8)%. The maximum binding rate of 131I-4E5 to Raji cells was (36.1 ± 2.6) 4E5 antibody was added to the serum after 3 days of radiochemical purity was still> 90%; tumor-bearing nude mice injected with 131I-4E5 antibody, with the extension of time, the tumor part of the radioactive concentration increased gradually, at 72 h tumor imaging was the most clear, T / NT value at this time up to 3.2. Conclusion The 131I-4E5 antibody has the ability of targeted localization in nude mice bearing lymphoma and can obtain good radioimmunoimaging images, which lays the foundation for the further use of 131I-4E5 for radioimmunotherapy targeting lymphoma CD80.